The University of Oxford has resumed its clinical trials of Covid-19 vaccine after being paused for several days due to the illness of one of the volunteers participating in the experiments.
The decision to resume the trials came after a trial review was conducted by an independent committee and the British Medicines and Healthcare products Regulatory Agency, Oxford University announced.
AstraZeneca pharmaceutical company, which is developing the vaccine in cooperation with the university, announced that the trials have been temporarily stopped to investigate whether the reported side effect is related to the vaccine.
The Oxford University vaccine is among the most promising vaccines that the world expects to reach the stage of manufacturing in an effort to reduce infection with the Coronavirus.
The vaccine will be available by the end of this year or early next year,AstraZeneca hopes.
The potential AstraZeneca vaccine is one of nine around the world currently in late-stage Phase 3 trials.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Belgium leading in EU Covid-19 infection rate
EU weighs buying Roche, Abbott rapid Covid tests amid limited supplies
US-backed Karabakh truce crumbles within hours
Nationwide strike underway: Belarus opposition leader
Tanker operator thanks Britain for storming vessel after stowaways turned hostile
France may be experiencing 100,000 new Covid cases per day
Oxford Covid-19 vaccine trials produce robust immune response in elderly
Belarus police use stun grenades against protesters
Spain declares virus emergency